Following encouraging results from Johnson & Johnson's experimental vaccine test in monkeys showing that a single dose is sufficient to protect them from the coronavirus, the final human trial of the vaccine began in the United States on Thursday.
The test results were published in the scientific journal Nature, and according to the article, 6 out of 6 monkeys who were injected with the vaccine received full protection against lung disease, and 5 out of 6 also developed antibodies that protect against coronavirus infection.
Dr. Paul Stoffels, chief scientist at J&J, said it would be possible to test a single dose of the vaccine in humans and see if it has a protective effect against the virus. Stoffels believes that a single dose of the vaccine has a significant advantage in eliminating the logistical cost of getting people back to the clinic to re-administer the vaccine.
J&J has received government aid in the amount of $ 456 million in a government program aimed at accelerating the production of a vaccine to combat the coronavirus pandemic. The company plans to begin a large-scale third phase with a single dose of vaccine in the second half of September. A study with two doses of vaccine will begin around the same time. If the company nevertheless brings the experiment to its logical conclusion, this device may become a gold mine for it. And the company's capitalization will skyrocket just like the stock price.
The test results were published in the scientific journal Nature, and according to the article, 6 out of 6 monkeys who were injected with the vaccine received full protection against lung disease, and 5 out of 6 also developed antibodies that protect against coronavirus infection.
Dr. Paul Stoffels, chief scientist at J&J, said it would be possible to test a single dose of the vaccine in humans and see if it has a protective effect against the virus. Stoffels believes that a single dose of the vaccine has a significant advantage in eliminating the logistical cost of getting people back to the clinic to re-administer the vaccine.
J&J has received government aid in the amount of $ 456 million in a government program aimed at accelerating the production of a vaccine to combat the coronavirus pandemic. The company plans to begin a large-scale third phase with a single dose of vaccine in the second half of September. A study with two doses of vaccine will begin around the same time. If the company nevertheless brings the experiment to its logical conclusion, this device may become a gold mine for it. And the company's capitalization will skyrocket just like the stock price.